Rifabutin + Rifabutin + Atazanavir + Ritonavir

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Antivirals/HIV

Conditions

Antivirals/HIV

Trial Timeline

Apr 1, 2008 → Aug 1, 2008

NCT ID

NCT00646776

About Rifabutin + Rifabutin + Atazanavir + Ritonavir

Rifabutin + Rifabutin + Atazanavir + Ritonavir is a phase 1 stage product being developed by Bristol Myers Squibb for Antivirals/HIV. The current trial status is completed. This product is registered under clinical trial identifier NCT00646776. Target conditions include Antivirals/HIV.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00646776	Phase 1	Completed	Apr 1, 2008	Aug 1, 2008	Antivirals/HIV